, Tracking Stock Market Picks
Enter Symbol:
Angiodynamics, Inc. (ANGO) [hlAlert]

down 10.35 %

Angiodynamics, Inc. (ANGO) downgraded to Underperform with price target $12 by Wedbush

Posted on: Tuesday,  Jun 14, 2011  9:25 AM ET by Wedbush

Wedbush rated Underperform Angiodynamics, Inc. (NASDAQ: ANGO) on 06/14/2011, when the stock price was $13.07. Since
then, Angiodynamics, Inc. has gained 11.55% as of 01/08/2016's recent price of $14.58.
If you would have followed this Wedbush 's recommendation on ANGO, you would have lost 10.35% of your investment in 1669 days.

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/14/2011 9:25 AM Sell
13.07 12.00
as of 12/30/2011
1 Week up  1.13 %
1 Month up  2.05 %
3 Months down  -12.70 %
1 YTD down  -13.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/8/2010 3:25 PM Hold
13.95 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy